首页 > 最新文献

Journal of molecular and cellular cardiology最新文献

英文 中文
Pyruvate kinase splice variants in fibroblasts influence cardiac remodeling after myocardial infarction in male mice 成纤维细胞中丙酮酸激酶剪接变异影响雄性小鼠心肌梗死后的心脏重构。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-10 DOI: 10.1016/j.yjmcc.2025.07.005
Collin K. Wells , Daniel C. Nguyen , Robert E. Brainard , Lindsey A. McNally , Maleesha De Silva , Kenneth R. Brittian , Lauren Garrett , Madison S. Taylor , Yania Martinez-Ondaro , Caitlin Howard , Snigdha Suluru , Sujith Dassanayaka , Tamer M.A. Mohamed , Richa Singhal , Andrew A. Gibb , Pawel K. Lorkiewicz , Joseph B. Moore IV , Steven P. Jones , Bradford G. Hill
Fibroblasts are crucial for cardiac repair after myocardial infarction (MI). In response to signaling cues, they differentiate to phenotypes with robust capacities to synthesize and secrete extracellular matrix (ECM) and signaling molecules. Although activated fibroblast phenotypes are associated with pronounced changes in metabolism, it remains unclear how the metabolic network upholds the effector functions of fibroblasts in the infarcted heart. We found that two enzymes that could facilitate a phosphoenolpyruvate cycle, i.e. pyruvate kinase muscle isoform 2 (PKM2) and phosphoenolpyruvate carboxykinase 2 (PCK2), are elevated in the heart after MI. Although Pck2 deletion had no effect on post-MI remodeling, fibroblast-specific switching of Pkm2 to Pkm1 (fbPkm2 → 1) mitigated ventricular dilation, wall thinning, and losses in ejection fraction caused by MI. Despite these salutary effects, fbPkm2 → 1 switching did not alter cardiac fibrosis in vivo, nor did it affect collagen production, cytokine or chemokine secretion, myofibroblast differentiation markers, or transcriptional regulation in vitro. Nevertheless, Pkm2 → 1 splice variant switching increased myofibroblast contractile activity as well as influenced the metabolic phenotype of fibroblasts, as shown by increased pyruvate kinase activity, higher mitochondrial respiratory capacity, and elevation in glycolytic intermediate abundance. Despite these changes, Pkm2 → 1 switching had relatively minor effects on glucose carbon fate, as determined by stable isotope-resolved metabolomics. Nevertheless, these metabolic data demonstrate that cardiac fibroblasts exhibit minimal glucose-supported de novo glycine synthesis in vitro, yet possess high hexosamine and glucuronate biosynthetic pathway activity. Collectively, these findings reveal that fibroblast PKM isoforms influence post-MI remodeling, highlighting pyruvate kinase as a potential therapeutic target.
成纤维细胞对心肌梗死(MI)后的心脏修复至关重要。在对信号信号的响应中,它们分化为具有合成和分泌细胞外基质(ECM)和信号分子的强大能力的表型。尽管活化的成纤维细胞表型与代谢的显著变化有关,但代谢网络如何维持梗死心脏成纤维细胞的效应功能仍不清楚。我们发现两种促进磷酸烯醇丙酮酸循环的酶,即丙酮酸激酶肌肉异型2 (PKM2)和磷酸烯醇丙酮酸羧激酶2 (PCK2),在心肌梗死后的心脏中升高。尽管PCK2缺失对心肌梗死后的重塑没有影响,但PKM2向Pkm1 (fbPkm2 → 1)的成纤维细胞特异性转换减轻了心肌梗死引起的心室扩张、壁薄和射血分的损失。fbPkm2 → 1开关在体内不改变心脏纤维化,也不影响胶原生成、细胞因子或趋化因子分泌、肌成纤维细胞分化标志物或体外转录调节。然而,Pkm2 → 1剪接变异开关增加了肌成纤维细胞的收缩活性,并影响了成纤维细胞的代谢表型,如丙酮酸激酶活性增加、线粒体呼吸能力提高和糖酵解中间产物丰度升高所示。尽管有这些变化,Pkm2 → 1开关对葡萄糖碳命运的影响相对较小,这是由稳定的同位素分解代谢组学确定的。然而,这些代谢数据表明,心脏成纤维细胞在体外表现出最低限度的葡萄糖支持的从头合成甘氨酸,但具有高的己糖胺和葡萄糖醛酸生物合成途径活性。总的来说,这些发现表明成纤维细胞PKM异构体影响心肌梗死后的重塑,强调丙酮酸激酶是一个潜在的治疗靶点。
{"title":"Pyruvate kinase splice variants in fibroblasts influence cardiac remodeling after myocardial infarction in male mice","authors":"Collin K. Wells ,&nbsp;Daniel C. Nguyen ,&nbsp;Robert E. Brainard ,&nbsp;Lindsey A. McNally ,&nbsp;Maleesha De Silva ,&nbsp;Kenneth R. Brittian ,&nbsp;Lauren Garrett ,&nbsp;Madison S. Taylor ,&nbsp;Yania Martinez-Ondaro ,&nbsp;Caitlin Howard ,&nbsp;Snigdha Suluru ,&nbsp;Sujith Dassanayaka ,&nbsp;Tamer M.A. Mohamed ,&nbsp;Richa Singhal ,&nbsp;Andrew A. Gibb ,&nbsp;Pawel K. Lorkiewicz ,&nbsp;Joseph B. Moore IV ,&nbsp;Steven P. Jones ,&nbsp;Bradford G. Hill","doi":"10.1016/j.yjmcc.2025.07.005","DOIUrl":"10.1016/j.yjmcc.2025.07.005","url":null,"abstract":"<div><div>Fibroblasts are crucial for cardiac repair after myocardial infarction (MI). In response to signaling cues, they differentiate to phenotypes with robust capacities to synthesize and secrete extracellular matrix (ECM) and signaling molecules. Although activated fibroblast phenotypes are associated with pronounced changes in metabolism, it remains unclear how the metabolic network upholds the effector functions of fibroblasts in the infarcted heart. We found that two enzymes that could facilitate a phosphoenolpyruvate cycle, i.e. pyruvate kinase muscle isoform 2 (PKM2) and phosphoenolpyruvate carboxykinase 2 (PCK2), are elevated in the heart after MI. Although <em>Pck2</em> deletion had no effect on post-MI remodeling, fibroblast-specific switching of <em>Pkm2</em> to <em>Pkm1</em> (fb<em>Pkm2 → 1</em>) mitigated ventricular dilation, wall thinning, and losses in ejection fraction caused by MI. Despite these salutary effects, fb<em>Pkm2 → 1</em> switching did not alter cardiac fibrosis in vivo, nor did it affect collagen production, cytokine or chemokine secretion, myofibroblast differentiation markers, or transcriptional regulation in vitro. Nevertheless, <em>Pkm2 → 1</em> splice variant switching increased myofibroblast contractile activity as well as influenced the metabolic phenotype of fibroblasts, as shown by increased pyruvate kinase activity, higher mitochondrial respiratory capacity, and elevation in glycolytic intermediate abundance. Despite these changes, <em>Pkm2 → 1</em> switching had relatively minor effects on glucose carbon fate, as determined by stable isotope-resolved metabolomics. Nevertheless, these metabolic data demonstrate that cardiac fibroblasts exhibit minimal glucose-supported de novo glycine synthesis in vitro, yet possess high hexosamine and glucuronate biosynthetic pathway activity. Collectively, these findings reveal that fibroblast PKM isoforms influence post-MI remodeling, highlighting pyruvate kinase as a potential therapeutic target.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"206 ","pages":"Pages 11-26"},"PeriodicalIF":4.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Soluble αKlotho interacts with Hsp90aa1 to inhibit the chaperone machinery-mediated Hif1α stabilization and alleviate CKD-induced vascular calcification 可溶性α - klotho与Hsp90aa1相互作用,抑制伴侣机制介导的Hif1α稳定,减轻ckd诱导的血管钙化。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-05 DOI: 10.1016/j.yjmcc.2025.07.003
Fengyang Xu , Jialin Guo , Yunyun Guo , Jiaxin Ma , Wentao Sang , Xiangkai Zhao , Jian Zhang , Tonghui Xu , Feng Xu , Yuguo Chen
Recent studies have highlighted the significance of soluble αKlotho in renal dysfunction-associated vascular health, however, the underlying molecular mechanisms by which soluble αKlotho maintains the vascular smooth muscle cells (VSMCs) phenotype and prevents vascular calcification remain unclear. Clinical analyses revealed an inverse correlation between circulating αKlotho levels and vascular calcification severity in early CKD patients. Recombinant protein or lentiviral vector transfection of soluble αKlotho significantly suppressed the osteogenic transdifferentiation of VSMCs in vitro. AAV-mediated overexpression of soluble αKlotho in VSMCs remarkably reduced vascular calcification without altering circulating soluble αKlotho levels or mineral metabolism in mice under a high-phosphate diet after nephrectomy. We also employed a combination of transcriptomics and proteomics approaches, as well as in vitro and in vivo vascular calcification models, and determined that soluble αKlotho specifically suppressed Hsp90aa1 activation-mediated osteogenic transdifferentiation of VSMCs and vascular calcification. The Hsp90aa1-specific inhibitor, 17-AAG, acted as an efficient therapeutic approach to attenuate vascular calcification in vivo and in vitro. Moreover, we revealed that the phosphorylation of Hsp90aa1 at Thr5/7 modulated its chaperone activity to stabilize Hif1α, thereby playing a causative role in the pathogenesis of vascular calcification. Upregulation of soluble αKlotho expression in VSMCs enhanced the interaction with Hsp90aa1 and blunted the phosphorylation of Hsp90aa1 at Thr5/7, which abolished Hsp90aa1-Hif1α axis activation in response to osteogenic induction. Our findings revealed a crucial pathway that soluble αKlotho interacts with Hsp90aa1 and suppresses the activation of the Hsp90aa1-Hif1α axis, which is involved in the osteogenic transdifferentiation of VSMCs and vascular calcification. Targeting Hsp90 may be a promising strategy for vascular calcification treatment, as various HSP90 inhibitors have been used for a range of clinical conditions.
最近的研究强调了可溶性αKlotho在肾功能障碍相关血管健康中的重要性,然而,可溶性αKlotho维持血管平滑肌细胞(VSMCs)表型和防止血管钙化的潜在分子机制尚不清楚。临床分析显示,早期CKD患者循环α - klotho水平与血管钙化严重程度呈负相关。重组蛋白或慢病毒载体转染可溶性α - klotho可显著抑制体外VSMCs的成骨转分化。高磷酸盐饮食小鼠肾切除术后,aav介导的可溶性α - klotho在VSMCs中过表达可显著降低血管钙化,而不改变循环可溶性α - klotho水平或矿物质代谢。我们还采用转录组学和蛋白质组学相结合的方法,以及体外和体内血管钙化模型,确定可溶性αKlotho特异性抑制Hsp90aa1激活介导的VSMCs成骨转分化和血管钙化。hsp90aa1特异性抑制剂17-AAG是一种有效的治疗方法,可在体内和体外减轻血管钙化。此外,我们发现Hsp90aa1在Thr5/7位点的磷酸化可调节其伴侣蛋白活性,从而稳定Hif1α,从而在血管钙化的发病机制中发挥致病作用。上调VSMCs中可溶性αKlotho的表达可增强Hsp90aa1与Hsp90aa1的相互作用,并减弱Hsp90aa1在Thr5/7位点的磷酸化,从而消除Hsp90aa1- hif1α轴在成骨诱导下的激活。我们的研究结果揭示了可溶性αKlotho与Hsp90aa1相互作用并抑制Hsp90aa1- hif1α轴的激活的关键途径,Hsp90aa1- hif1α轴参与了VSMCs的成骨转分化和血管钙化。靶向Hsp90可能是血管钙化治疗的一种有前途的策略,因为各种Hsp90抑制剂已用于一系列临床病症。
{"title":"Soluble αKlotho interacts with Hsp90aa1 to inhibit the chaperone machinery-mediated Hif1α stabilization and alleviate CKD-induced vascular calcification","authors":"Fengyang Xu ,&nbsp;Jialin Guo ,&nbsp;Yunyun Guo ,&nbsp;Jiaxin Ma ,&nbsp;Wentao Sang ,&nbsp;Xiangkai Zhao ,&nbsp;Jian Zhang ,&nbsp;Tonghui Xu ,&nbsp;Feng Xu ,&nbsp;Yuguo Chen","doi":"10.1016/j.yjmcc.2025.07.003","DOIUrl":"10.1016/j.yjmcc.2025.07.003","url":null,"abstract":"<div><div>Recent studies have highlighted the significance of soluble αKlotho in renal dysfunction-associated vascular health, however, the underlying molecular mechanisms by which soluble αKlotho maintains the vascular smooth muscle cells (VSMCs) phenotype and prevents vascular calcification remain unclear. Clinical analyses revealed an inverse correlation between circulating αKlotho levels and vascular calcification severity in early CKD patients. Recombinant protein or lentiviral vector transfection of soluble αKlotho significantly suppressed the osteogenic transdifferentiation of VSMCs in vitro. AAV-mediated overexpression of soluble αKlotho in VSMCs remarkably reduced vascular calcification without altering circulating soluble αKlotho levels or mineral metabolism in mice under a high-phosphate diet after nephrectomy. We also employed a combination of transcriptomics and proteomics approaches, as well as in vitro and in vivo vascular calcification models, and determined that soluble αKlotho specifically suppressed Hsp90aa1 activation-mediated osteogenic transdifferentiation of VSMCs and vascular calcification. The Hsp90aa1-specific inhibitor, 17-AAG, acted as an efficient therapeutic approach to attenuate vascular calcification in vivo and in vitro. Moreover, we revealed that the phosphorylation of Hsp90aa1 at Thr5/7 modulated its chaperone activity to stabilize Hif1α, thereby playing a causative role in the pathogenesis of vascular calcification. Upregulation of soluble αKlotho expression in VSMCs enhanced the interaction with Hsp90aa1 and blunted the phosphorylation of Hsp90aa1 at Thr5/7, which abolished Hsp90aa1-Hif1α axis activation in response to osteogenic induction. Our findings revealed a crucial pathway that soluble αKlotho interacts with Hsp90aa1 and suppresses the activation of the Hsp90aa1-Hif1α axis, which is involved in the osteogenic transdifferentiation of VSMCs and vascular calcification. Targeting Hsp90 may be a promising strategy for vascular calcification treatment, as various HSP90 inhibitors have been used for a range of clinical conditions.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Pages 100-116"},"PeriodicalIF":4.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management 糖尿病性心肌病的临床管理与病理生理学和诊断。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-05 DOI: 10.1016/j.yjmcc.2025.06.013
David Chen , Andrew Sindone , Michael L.H. Huang , Karlheinz Peter , Alicia J. Jenkins
Diabetes mellitus is associated with significant morbidity and premature mortality for which heart failure (HF) is a major cause. HF may be due to ischaemia, hypertension, valvular disease, uraemia, or a specific diabetic cardiomyopathy, and multiple causes may co-exist. A recent systematic review suggests that >40 % of people with type 2 diabetes have diastolic dysfunction without a reduction of cardiac systolic function. In people with type 1 diabetes without known cardiovascular disease, 16 % had systolic or diastolic dysfunction. Early diabetic cardiomyopathy is asymptomatic and can progress to symptomatic HF via increasing cardiomyocyte hypertrophy and death as well as cardiac fibrosis. The 5-year mortality rate for HF is similar or worse than many common cancers. There have been significant recent advances in HF treatment including sodium-glucose co-transport 2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin inhibitors (ARNi), and promising therapies such as finerenone and glucagon-like peptide-1 receptor agonists (GLP-1RA). SGLT2i, finerenone, and GLP-1RA may also have a role in HF prevention in asymptomatic diabetic cardiomyopathy. While there is currently no specific treatment for diabetic cardiomyopathy that goes beyond general HF treatment, there is promising research into innovative technologies such as gene and stem cell therapies. Also, digital technologies will likely have an increasing role in diabetic cardiomyopathy treatment. Herein we review the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy, with a focus on existing, emerging, and potentially promising novel therapies. We provide practical tables that summarise treatments at each stage as well as important practice points for commonly prescribed drugs.
糖尿病与显著的发病率和过早死亡相关,其中心力衰竭(HF)是主要原因。心衰可能是由于缺血、高血压、尿毒症或特定的糖尿病性心肌病引起的,多种原因可能并存。最近的一项系统综述表明,bbb40 %的2型糖尿病患者有舒张功能障碍,但心脏收缩功能没有降低。在没有已知心血管疾病的1型糖尿病患者中,16% %有收缩或舒张功能障碍。早期糖尿病心肌病是无症状的,可通过心肌细胞肥大和死亡增加以及心脏纤维化发展为症状性心衰。心衰的5年死亡率与许多常见癌症相似或更糟。最近在心衰治疗方面取得了重大进展,包括钠-葡萄糖共转运2抑制剂(SGLT2i)和血管紧张素受体- nepryysin抑制剂(ARNi),以及有希望的治疗方法,如细烯酮和胰高血糖素样肽-1受体激动剂(GLP-1RA)。SGLT2i、芬烯酮和GLP-1RA也可能在无症状糖尿病心肌病中预防心衰。虽然目前对于糖尿病性心肌病还没有超越一般心衰治疗的特殊治疗方法,但在基因和干细胞治疗等创新技术方面的研究很有前景。此外,数字技术可能在糖尿病心肌病治疗中发挥越来越大的作用。在此,我们回顾了糖尿病性心肌病的病理生理、诊断和治疗,重点介绍了现有的、新兴的和有潜力的新疗法。我们提供实用的表格,总结每个阶段的治疗以及常用处方药的重要实践要点。
{"title":"Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management","authors":"David Chen ,&nbsp;Andrew Sindone ,&nbsp;Michael L.H. Huang ,&nbsp;Karlheinz Peter ,&nbsp;Alicia J. Jenkins","doi":"10.1016/j.yjmcc.2025.06.013","DOIUrl":"10.1016/j.yjmcc.2025.06.013","url":null,"abstract":"<div><div>Diabetes mellitus is associated with significant morbidity and premature mortality for which heart failure (HF) is a major cause. HF may be due to ischaemia, hypertension, valvular disease, uraemia, or a specific diabetic cardiomyopathy, and multiple causes may co-exist. A recent systematic review suggests that &gt;40 % of people with type 2 diabetes have diastolic dysfunction without a reduction of cardiac systolic function. In people with type 1 diabetes without known cardiovascular disease, 16 % had systolic or diastolic dysfunction. Early diabetic cardiomyopathy is asymptomatic and can progress to symptomatic HF via increasing cardiomyocyte hypertrophy and death as well as cardiac fibrosis. The 5-year mortality rate for HF is similar or worse than many common cancers. There have been significant recent advances in HF treatment including sodium-glucose co-transport 2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin inhibitors (ARNi), and promising therapies such as finerenone and glucagon-like peptide-1 receptor agonists (GLP-1RA). SGLT2i, finerenone, and GLP-1RA may also have a role in HF prevention in asymptomatic diabetic cardiomyopathy. While there is currently no specific treatment for diabetic cardiomyopathy that goes beyond general HF treatment, there is promising research into innovative technologies such as gene and stem cell therapies. Also, digital technologies will likely have an increasing role in diabetic cardiomyopathy treatment. Herein we review the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy, with a focus on existing, emerging, and potentially promising novel therapies. We provide practical tables that summarise treatments at each stage as well as important practice points for commonly prescribed drugs.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"206 ","pages":"Pages 55-69"},"PeriodicalIF":4.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smooth muscle-specific HuR knockout attenuates vascular calcification 平滑肌特异性HuR敲除可减轻血管钙化。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-05 DOI: 10.1016/j.yjmcc.2025.07.002
Ang Chen, Peidong Yuan, Yue Lu, Chang Ma, Fei Xue, Jianmin Yang, Yun Zhang, Wencheng Zhang
Vascular calcification is a common pathological feature of atherosclerosis, chronic kidney disease, vascular injury and aging. Human antigen R (HuR), a widely expressed RNA-binding protein, plays a key role in the regulation of homeostasis and pathological conditions such as cancer and cardiovascular disease, but its role in vascular calcification remains unclear. In this study, we generated smooth muscle-specific HuR knockout (HuRSMKO) mice to investigate the function of HuR in vascular calcification. The HuR level increased under calcifying conditions, and high phosphate levels increased HuR expression via activating transcription factor 4 (ATF4). HuR overexpression exacerbated high phosphate-induced calcification, whereas HuR deficiency inhibited high phosphate-induced calcification in VSMCs. Smooth muscle-specific knockout of HuR protected against vascular calcification in vivo. Additionally, treatment with the HuR inhibitor CMLD-2 significantly attenuated calcification in mice. Mechanistically, HuR binds directly to Runt-related transcription factor 2 (Runx2) mRNA, increasing its stability and protein expression, which facilitates vascular calcification. These findings demonstrate that HuR plays a critical role in the regulation of vascular calcification through the posttranscriptional control of Runx2.
血管钙化是动脉粥样硬化、慢性肾病、血管损伤和衰老的共同病理特征。人抗原R (Human antigen R, HuR)是一种广泛表达的rna结合蛋白,在体内平衡和癌症、心血管疾病等病理状况的调节中起着关键作用,但在血管钙化中的作用尚不清楚。在这项研究中,我们制造了平滑肌特异性HuR敲除(HuRSMKO)小鼠来研究HuR在血管钙化中的功能。钙化条件下,HuR水平升高,高磷酸盐水平通过激活转录因子4 (ATF4)增加了HuR的表达。HuR过表达加剧了高磷酸盐诱导的钙化,而HuR缺乏抑制高磷酸盐诱导的VSMCs钙化。体内平滑肌特异性敲除HuR可防止血管钙化。此外,用HuR抑制剂CMLD-2治疗可显著减轻小鼠的钙化。从机制上讲,HuR直接结合runt相关转录因子2 (Runx2) mRNA,增加其稳定性和蛋白表达,促进血管钙化。这些发现表明,HuR通过Runx2的转录后调控,在血管钙化的调控中起着关键作用。
{"title":"Smooth muscle-specific HuR knockout attenuates vascular calcification","authors":"Ang Chen,&nbsp;Peidong Yuan,&nbsp;Yue Lu,&nbsp;Chang Ma,&nbsp;Fei Xue,&nbsp;Jianmin Yang,&nbsp;Yun Zhang,&nbsp;Wencheng Zhang","doi":"10.1016/j.yjmcc.2025.07.002","DOIUrl":"10.1016/j.yjmcc.2025.07.002","url":null,"abstract":"<div><div>Vascular calcification is a common pathological feature of atherosclerosis, chronic kidney disease, vascular injury and aging. Human antigen R (HuR), a widely expressed RNA-binding protein, plays a key role in the regulation of homeostasis and pathological conditions such as cancer and cardiovascular disease, but its role in vascular calcification remains unclear. In this study, we generated smooth muscle-specific HuR knockout (HuR<sup>SMKO</sup>) mice to investigate the function of HuR in vascular calcification. The HuR level increased under calcifying conditions, and high phosphate levels increased HuR expression via activating transcription factor 4 (ATF4). HuR overexpression exacerbated high phosphate-induced calcification, whereas HuR deficiency inhibited high phosphate-induced calcification in VSMCs. Smooth muscle-specific knockout of HuR protected against vascular calcification in vivo. Additionally, treatment with the HuR inhibitor CMLD-2 significantly attenuated calcification in mice. Mechanistically, HuR binds directly to Runt-related transcription factor 2 (Runx2) mRNA, increasing its stability and protein expression, which facilitates vascular calcification. These findings demonstrate that HuR plays a critical role in the regulation of vascular calcification through the posttranscriptional control of Runx2.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Pages 117-128"},"PeriodicalIF":4.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms” [Journal of Molecular and Cellular Cardiology. 194 (2024): 118–132] “心房颤动与癌症、抗癌治疗和潜在机制”的更正[j] . Molecular and Cellular Cardiology. 194(2024): 118-132。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-04 DOI: 10.1016/j.yjmcc.2025.06.010
Adnan Shaaban , Shane S. Scott , Ashley N. Greenlee , Nkongho Binda , Noor Ali , Averie Webb , Shuliang Guo , Najhee Purdy , Nicholas Pennza , Alma Habib , Somayya J. Mohammad , Sakima A. Smith
{"title":"Corrigendum to “Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms” [Journal of Molecular and Cellular Cardiology. 194 (2024): 118–132]","authors":"Adnan Shaaban ,&nbsp;Shane S. Scott ,&nbsp;Ashley N. Greenlee ,&nbsp;Nkongho Binda ,&nbsp;Noor Ali ,&nbsp;Averie Webb ,&nbsp;Shuliang Guo ,&nbsp;Najhee Purdy ,&nbsp;Nicholas Pennza ,&nbsp;Alma Habib ,&nbsp;Somayya J. Mohammad ,&nbsp;Sakima A. Smith","doi":"10.1016/j.yjmcc.2025.06.010","DOIUrl":"10.1016/j.yjmcc.2025.06.010","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Page 99"},"PeriodicalIF":4.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome” [Journal of Molecular and Cellular Cardiology 138 (2020) 291–303] 线粒体硫氧还蛋白-2维持HCN4表达并预防氧化应激介导的病窦综合征[j] . Molecular and Cellular Cardiology 138(2020) 291-303。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-02 DOI: 10.1016/j.yjmcc.2025.06.007
Bicheng Yang , Yanrui Huang , Haifeng Zhang , Yan Huang , Huanjiao Jenny Zhou , Lawrence Young , Haipeng Xiao , Wang Min
{"title":"Corrigendum to “Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome” [Journal of Molecular and Cellular Cardiology 138 (2020) 291–303]","authors":"Bicheng Yang ,&nbsp;Yanrui Huang ,&nbsp;Haifeng Zhang ,&nbsp;Yan Huang ,&nbsp;Huanjiao Jenny Zhou ,&nbsp;Lawrence Young ,&nbsp;Haipeng Xiao ,&nbsp;Wang Min","doi":"10.1016/j.yjmcc.2025.06.007","DOIUrl":"10.1016/j.yjmcc.2025.06.007","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Page 85"},"PeriodicalIF":4.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcium binding to troponin C is required for activation of the myosin-containing thick filaments in rat cardiac trabeculae 钙与肌钙蛋白C结合是激活大鼠心脏小梁含肌球蛋白粗丝所必需的。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-07-01 DOI: 10.1016/j.yjmcc.2025.06.012
Michaeljohn Kalakoutis , Yanhong Wang , Emma Smith , Alice Arcidiacono , Cameron Hill , Samina Juma , Atsuki Fukutani , Elisabetta Brunello , Luca Fusi , Malcolm Irving
Contraction of the muscular walls of the heart is driven by an interaction between myosin motors from the thick filaments and actin sites in the thin filaments. Each heartbeat is triggered by calcium binding to troponin in the thin filaments, which unblocks the myosin-binding sites on actin. The strength and speed of contraction is also modulated by the availability of myosin motors, which are sequestered in a helical array on the surface of the thick filaments between heartbeats. The signalling pathway controlling release of the motors from this array during the heartbeat is unknown, but there are three general hypotheses: thick-filament mechano-sensing, thin-to-thick filament signalling, and direct calcium signalling to the thick filament. Here we tested the third hypothesis by replacing the native calcium-binding subunit of troponin (TnC) with a variant which cannot bind calcium. Demembranated trabeculae from rat heart containing this variant generated no active force on addition of calcium. We measured calcium-induced release of myosin motors from the sequestered state by X-ray diffraction and from the orientation of fluorescent probes on the myosin regulatory light chain. Both methods showed the expected calcium-dependent changes in the conformation of the myosin motors in trabeculae containing native TnC, but all these changes were abolished in those containing the TnC variant that cannot bind calcium. We conclude that thick filament activation in rat heart trabeculae is not due to direct binding of calcium to thick filaments, but is mediated by calcium activation of the thin filaments by mechano-sensing or thin-to-thick filament signalling.
心脏肌壁的收缩是由来自粗纤维的肌凝蛋白马达和来自细纤维的肌动蛋白位点之间的相互作用驱动的。每次心跳都是由钙与细纤维中的肌钙蛋白结合引发的,这就打开了肌动蛋白上的肌球蛋白结合位点。收缩的强度和速度也由肌凝蛋白马达的可用性来调节,肌凝蛋白马达以螺旋阵列的形式隔离在心跳之间的粗纤维表面。在心跳期间,控制马达从该阵列释放的信号通路尚不清楚,但有三种普遍的假设:厚丝机械传感、薄到厚丝信号和直接钙信号到厚丝。在这里,我们通过用一种不能结合钙的变体取代肌钙蛋白(TnC)的天然钙结合亚基来检验第三种假设。含该变体的大鼠心脏脱膜小梁在加钙时不产生活性。我们通过x射线衍射和荧光探针在肌球蛋白调节光链上的取向测量了钙诱导的肌球蛋白马达从隔离状态释放。两种方法都显示了含有天然TnC的小梁中肌球蛋白马达构象的钙依赖性变化,但在含有不能结合钙的TnC变体的小梁中,所有这些变化都被消除了。我们得出结论,大鼠心脏小梁的粗丝激活不是由于钙与粗丝的直接结合,而是由钙通过机械传感或细到粗的纤维信号激活细丝介导的。
{"title":"Calcium binding to troponin C is required for activation of the myosin-containing thick filaments in rat cardiac trabeculae","authors":"Michaeljohn Kalakoutis ,&nbsp;Yanhong Wang ,&nbsp;Emma Smith ,&nbsp;Alice Arcidiacono ,&nbsp;Cameron Hill ,&nbsp;Samina Juma ,&nbsp;Atsuki Fukutani ,&nbsp;Elisabetta Brunello ,&nbsp;Luca Fusi ,&nbsp;Malcolm Irving","doi":"10.1016/j.yjmcc.2025.06.012","DOIUrl":"10.1016/j.yjmcc.2025.06.012","url":null,"abstract":"<div><div>Contraction of the muscular walls of the heart is driven by an interaction between myosin motors from the thick filaments and actin sites in the thin filaments. Each heartbeat is triggered by calcium binding to troponin in the thin filaments, which unblocks the myosin-binding sites on actin. The strength and speed of contraction is also modulated by the availability of myosin motors, which are sequestered in a helical array on the surface of the thick filaments between heartbeats. The signalling pathway controlling release of the motors from this array during the heartbeat is unknown, but there are three general hypotheses: thick-filament mechano-sensing, thin-to-thick filament signalling, and direct calcium signalling to the thick filament. Here we tested the third hypothesis by replacing the native calcium-binding subunit of troponin (TnC) with a variant which cannot bind calcium. Demembranated trabeculae from rat heart containing this variant generated no active force on addition of calcium. We measured calcium-induced release of myosin motors from the sequestered state by X-ray diffraction and from the orientation of fluorescent probes on the myosin regulatory light chain. Both methods showed the expected calcium-dependent changes in the conformation of the myosin motors in trabeculae containing native TnC, but all these changes were abolished in those containing the TnC variant that cannot bind calcium. We conclude that thick filament activation in rat heart trabeculae is not due to direct binding of calcium to thick filaments, but is mediated by calcium activation of the thin filaments by mechano-sensing or thin-to-thick filament signalling.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Pages 129-138"},"PeriodicalIF":4.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermedin1–53 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation 中间体1 - 53通过线粒体sirt3介导的SOD2去乙酰化改善衰老相关的心脏重塑和功能障碍
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-06-30 DOI: 10.1016/j.yjmcc.2025.06.011
Deng-Ren Ji , Rui Chang , Shi-Meng Liu , Ya-Rong Zhang , Jie Zhao , Yan-Rong Yu , Mo-Zhi Jia , Ning Wu , Hui-Fang Tang , Chao-Shu Tang , Ye-Bo Zhou , Yong-Fen Qi
The aging-associated cardiac remodeling (AACR) is characterized by myocardial hypertrophy, fibrosis and cardiac dysfunction, which could be further aggravated by angiotensin II (Ang II) and pressure-overload in aged people. In this study, we aimed to investigate the roles and mechanisms of intermedin153 (IMD153), an endogenous peptide, in AACR in aged mice (18 months) with subcutaneous Ang II infusion (1000 ng/kg/min) for 2 weeks via osmotic pump or transverse abdominal aorta constriction (AAC) surgery for 4 weeks. In aged mice undergoing Ang II infusion or AAC surgery, the results showed that the mRNA and protein levels of IMD153 were significantly reduced, but the protein levels of its receptor complex components were increased; blood pressure (BP), myocardial hypertrophy, fibrosis, and cardiac dysfunction were notably aggravated; mitochondrial Sirtuin 3 (SIRT3) protein level, superoxide dismutase 2 (SOD2) activity and ATP production were remarkably decreased, but acetylated SOD2 (acSOD2) protein level was markedly increased when compared with the old mice. The above alterations could be effectively alleviated by the subcutaneous IMD153 administration (5 ng/kg/min) for 2 or 4 weeks. In Ang II-stimulated cardiomyocytes, IMD153 treatment improved Ang II-induced mitochondrial dysfunction and oxidative distress, up-regulated SIRT3 protein expression, and reduced acSOD2 protein level, which were notably weakened by SIRT3 knockdown. Moreover, SIRT3 deletion attenuated the protective effects of IMD153 on myocardial hypertrophy, fibrosis, and cardiac dysfunction in aged mice undergoing Ang II infusion. In addition, the effect of IMD153 on up-regulating SIRT3 expression was effectively inhibited by the antagonism of IMD153 receptor or blocking PI3K/Akt, cAMP/PKA and AMPK signaling pathways in vitro. Taken together, IMD153 alleviated AACR and cardiac dysfunction aggravated by Ang II or pressure-overload involving the improvement of mitochondrial oxidative distress through SIRT3-medaiated SOD2 deacetylation.
衰老相关心脏重构(AACR)以心肌肥大、纤维化和心功能障碍为特征,老年人血管紧张素II (Ang II)和压力过载可进一步加重AACR。在这项研究中,我们旨在研究内源性肽intermedin1-53 (IMD1-53)在老龄小鼠(18个月)AACR中的作用和机制,通过渗透泵皮下注射(1000 ng/kg/min) 2周或腹横主动脉缩窄(AAC)手术4周。结果表明,老龄小鼠经Angⅱ输注或AAC手术后,IMD1-53 mRNA和蛋白水平显著降低,但其受体复合物组分蛋白水平升高;血压(BP)、心肌肥大、纤维化、心功能障碍明显加重;与老龄小鼠相比,线粒体Sirtuin 3 (SIRT3)蛋白水平、超氧化物歧化酶2 (SOD2)活性和ATP生成显著降低,而乙酰化SOD2 (acSOD2)蛋白水平显著升高。IMD1-53皮下给药(5ng /kg/min) 2或4周可有效缓解上述变化。在Ang ii刺激的心肌细胞中,IMD1-53处理改善了Ang ii诱导的线粒体功能障碍和氧化应激,上调了SIRT3蛋白表达,降低了acSOD2蛋白水平,SIRT3敲低显著削弱了acSOD2蛋白水平。此外,SIRT3缺失减弱了IMD1-53对灌注Ang II的老年小鼠心肌肥大、纤维化和心功能障碍的保护作用。此外,IMD1-53在体外可通过拮抗IMD1-53受体或阻断PI3K/Akt、cAMP/PKA和AMPK信号通路,有效抑制其上调SIRT3表达的作用。综上所述,IMD1-53通过sirt3介导的SOD2去乙酰化改善线粒体氧化应激,减轻了Ang II或压力过载加重的AACR和心功能障碍。
{"title":"Intermedin1–53 improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation","authors":"Deng-Ren Ji ,&nbsp;Rui Chang ,&nbsp;Shi-Meng Liu ,&nbsp;Ya-Rong Zhang ,&nbsp;Jie Zhao ,&nbsp;Yan-Rong Yu ,&nbsp;Mo-Zhi Jia ,&nbsp;Ning Wu ,&nbsp;Hui-Fang Tang ,&nbsp;Chao-Shu Tang ,&nbsp;Ye-Bo Zhou ,&nbsp;Yong-Fen Qi","doi":"10.1016/j.yjmcc.2025.06.011","DOIUrl":"10.1016/j.yjmcc.2025.06.011","url":null,"abstract":"<div><div>The aging-associated cardiac remodeling (AACR) is characterized by myocardial hypertrophy, fibrosis and cardiac dysfunction, which could be further aggravated by angiotensin II (Ang II) and pressure-overload in aged people. In this study, we aimed to investigate the roles and mechanisms of intermedin<sub>1</sub><sub>–</sub><sub>53</sub> (IMD<sub>1</sub><sub>–</sub><sub>53</sub>), an endogenous peptide, in AACR in aged mice (18 months) with subcutaneous Ang II infusion (1000 ng/kg/min) for 2 weeks via osmotic pump or transverse abdominal aorta constriction (AAC) surgery for 4 weeks. In aged mice undergoing Ang II infusion or AAC surgery, the results showed that the mRNA and protein levels of IMD<sub>1</sub><sub>–</sub><sub>53</sub> were significantly reduced, but the protein levels of its receptor complex components were increased; blood pressure (BP), myocardial hypertrophy, fibrosis, and cardiac dysfunction were notably aggravated; mitochondrial Sirtuin 3 (SIRT3) protein level, superoxide dismutase 2 (SOD2) activity and ATP production were remarkably decreased, but acetylated SOD2 (acSOD2) protein level was markedly increased when compared with the old mice. The above alterations could be effectively alleviated by the subcutaneous IMD<sub>1</sub><sub>–</sub><sub>53</sub> administration (5 ng/kg/min) for 2 or 4 weeks. In Ang II-stimulated cardiomyocytes, IMD<sub>1</sub><sub>–</sub><sub>53</sub> treatment improved Ang II-induced mitochondrial dysfunction and oxidative distress, up-regulated SIRT3 protein expression, and reduced acSOD2 protein level, which were notably weakened by SIRT3 knockdown. Moreover, SIRT3 deletion attenuated the protective effects of IMD<sub>1</sub><sub>–</sub><sub>53</sub> on myocardial hypertrophy, fibrosis, and cardiac dysfunction in aged mice undergoing Ang II infusion. In addition, the effect of IMD<sub>1</sub><sub>–</sub><sub>53</sub> on up-regulating SIRT3 expression was effectively inhibited by the antagonism of IMD<sub>1</sub><sub>–</sub><sub>53</sub> receptor or blocking PI3K/Akt, cAMP/PKA and AMPK signaling pathways in vitro. Taken together, IMD<sub>1</sub><sub>–</sub><sub>53</sub> alleviated AACR and cardiac dysfunction aggravated by Ang II or pressure-overload involving the improvement of mitochondrial oxidative distress through SIRT3-medaiated SOD2 deacetylation.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Pages 86-98"},"PeriodicalIF":4.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Hypoxic compound exercise improves cardiac function in Drosophila high fructose diet via KHK” [Journal Of Molecular And Cellular Cardiol. 201(2025):95–104] “低氧复合运动通过KHK提高果蝇高果糖饮食的心脏功能”的更正[Journal Of Molecular And Cellular Cardiol. 201(2025): 95-104]
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-06-28 DOI: 10.1016/j.yjmcc.2025.06.006
Xu Ping, Qiufang Li, Meng Ding, Zhengwen Yu, Qin Yi, Yuepeng Li, Wenzhi Gu, Ping Zhang, Zike Zhang, Lan Zheng
{"title":"Corrigendum to “Hypoxic compound exercise improves cardiac function in Drosophila high fructose diet via KHK” [Journal Of Molecular And Cellular Cardiol. 201(2025):95–104]","authors":"Xu Ping,&nbsp;Qiufang Li,&nbsp;Meng Ding,&nbsp;Zhengwen Yu,&nbsp;Qin Yi,&nbsp;Yuepeng Li,&nbsp;Wenzhi Gu,&nbsp;Ping Zhang,&nbsp;Zike Zhang,&nbsp;Lan Zheng","doi":"10.1016/j.yjmcc.2025.06.006","DOIUrl":"10.1016/j.yjmcc.2025.06.006","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Page 84"},"PeriodicalIF":4.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular mechanism for the interaction of MOG1 with the intracellular loop II of cardiac sodium channel Nav1.5 and its role in arrhythmias MOG1与心脏钠通道Nav1.5胞内环II相互作用的分子机制及其在心律失常中的作用。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-06-19 DOI: 10.1016/j.yjmcc.2025.06.005
Xuemei Bai , Zhijie Wang , Hongbo Xiong , Chipeng Yan , Yufeng Yao , Chengqi Xu , Hui Li , Qing K. Wang
SCN5A encodes the cardiac sodium channel α-subunit Nav1.5, and its variants cause long QT syndrome (LQTS), Brugada syndrome (BrS) and other arrhythmias. MOG1 interacts with Nav1.5 to increase cardiac sodium current densities, however, molecular mechanisms remain poorly defined. The objectives of this study were to identify the crucial structural elements responsible for the interaction between MOG1 and Nav1.5 intracellular Loop II, and determine the significance of this interaction to cardiac arrhythmias. Whole-cell patch-clamping was used to record sodium current INa in tsA201 and neonatal rat primary cardiomyocytes. Glutathione S-transferase (GST) pull-down assays were used to characterize protein-protein interactions. Mutagenesis was used to create deletions and point mutations. Characterization of large deletions and small deletions of Nav1.5 Loop II 940–1200 defined the MOG1-interacting domain to V1190-H1200. Point mutation analysis revealed that amino acids R1195, Y1199 and H1200 were involved in MOG1-Nav1.5 Loop II interaction. Two variants of MOG1-interacting domain from human patients showed important functional effects. Variant p.R1195C was identified in two individuals with cardiac arrhythmias in ClinVar, weakened the interaction between Nav1.5 and MOG1, and reduced MOG1-enhanced cardiac sodium current densities. Variant p.Y1199S was identified in one individual with LQTS and one with cardiac arrhythmias, generated late INa, weakened the interaction between Nav1.5 and MOG1, and reduced MOG1-enhanced cardiac sodium current densities. This study identifies three critical amino acids R1195, Y1199 and H1200 of Nav1.5 Loop II for interaction with MOG1, and reveals the molecular mechanisms by which variants p.R1195C and p.Y1199S in MOG1-interacting domain cause LQTS and cardiac arrythmias.
SCN5A编码心脏钠通道α-亚基Nav1.5,其变异可引起长QT综合征(LQTS)、Brugada综合征(BrS)等心律失常。然而,MOG1与Nav1.5相互作用增加心脏钠电流密度的分子机制仍不明确。本研究的目的是确定MOG1和Nav1.5细胞内环路II之间相互作用的关键结构元件,并确定这种相互作用对心律失常的意义。采用全细胞膜片钳法记录tsA201和新生大鼠原代心肌细胞中的钠电流INa。谷胱甘肽s -转移酶(GST)下拉试验用于表征蛋白质-蛋白质相互作用。诱变用于产生缺失和点突变。Nav1.5 Loop II 940-1200的大缺失和小缺失将mog1相互作用域定义为V1190-H1200。点突变分析显示,氨基酸R1195、Y1199和H1200参与了MOG1-Nav1.5 Loop II互作。来自人类患者的mog1相互作用域的两个变体显示出重要的功能作用。变异p.R1195C在两例ClinVar心律失常患者中被发现,削弱了Nav1.5和MOG1之间的相互作用,降低了MOG1增强的心脏钠电流密度。变异p.Y1199S在1例LQTS患者和1例心律失常患者中被鉴定出,产生晚期INa,削弱Nav1.5和MOG1之间的相互作用,降低MOG1增强的心脏钠电流密度。本研究鉴定了Nav1.5 Loop II中与MOG1相互作用的三个关键氨基酸R1195、Y1199和H1200,揭示了MOG1相互作用域p.R1195C和p.Y1199S变异体导致LQTS和心律失常的分子机制。
{"title":"Molecular mechanism for the interaction of MOG1 with the intracellular loop II of cardiac sodium channel Nav1.5 and its role in arrhythmias","authors":"Xuemei Bai ,&nbsp;Zhijie Wang ,&nbsp;Hongbo Xiong ,&nbsp;Chipeng Yan ,&nbsp;Yufeng Yao ,&nbsp;Chengqi Xu ,&nbsp;Hui Li ,&nbsp;Qing K. Wang","doi":"10.1016/j.yjmcc.2025.06.005","DOIUrl":"10.1016/j.yjmcc.2025.06.005","url":null,"abstract":"<div><div><em>SCN5A</em> encodes the cardiac sodium channel α-subunit Na<sub>v</sub>1.5, and its variants cause long QT syndrome (LQTS), Brugada syndrome (BrS) and other arrhythmias. MOG1 interacts with Na<sub>v</sub>1.5 to increase cardiac sodium current densities, however, molecular mechanisms remain poorly defined. The objectives of this study were to identify the crucial structural elements responsible for the interaction between MOG1 and Na<sub>v</sub>1.5 intracellular Loop II, and determine the significance of this interaction to cardiac arrhythmias. Whole-cell patch-clamping was used to record sodium current <em>I</em><sub><em>Na</em></sub> in tsA201 and neonatal rat primary cardiomyocytes. Glutathione S-transferase (GST) pull-down assays were used to characterize protein-protein interactions. Mutagenesis was used to create deletions and point mutations. Characterization of large deletions and small deletions of Na<sub>v</sub>1.5 Loop II 940–1200 defined the MOG1-interacting domain to V<sub>1190</sub>-H<sub>1200</sub>. Point mutation analysis revealed that amino acids R<sub>1195</sub>, Y<sub>1199</sub> and H<sub>1200</sub> were involved in MOG1-Na<sub>v</sub>1.5 Loop II interaction. Two variants of MOG1-interacting domain from human patients showed important functional effects. Variant p.R1195C was identified in two individuals with cardiac arrhythmias in ClinVar, weakened the interaction between Na<sub>v</sub>1.5 and MOG1, and reduced MOG1-enhanced cardiac sodium current densities. Variant p.Y1199S was identified in one individual with LQTS and one with cardiac arrhythmias, generated late <em>I</em><sub><em>Na</em></sub>, weakened the interaction between Na<sub>v</sub>1.5 and MOG1, and reduced MOG1-enhanced cardiac sodium current densities. This study identifies three critical amino acids R<sub>1195</sub>, Y<sub>1199</sub> and H<sub>1200</sub> of Na<sub>v</sub>1.5 Loop II for interaction with MOG1, and reveals the molecular mechanisms by which variants p.R1195C and p.Y1199S in MOG1-interacting domain cause LQTS and cardiac arrythmias.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"205 ","pages":"Pages 68-83"},"PeriodicalIF":4.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of molecular and cellular cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1